Zifan Li
Zifan Li has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Shihua Yang
Cancer Hospital of Dalian University of Technology, Shenyang, China
2 shared publications - Li-Da Su
Neuroscience Care Unit, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
1 shared publication - Peng Han
Department of Neurosurgery, Dalian Municipal Central Hospital, Central Hospital of Dalian University of Technology, Dalian, China
1 shared publication Peng Yu
Department of Neurosurgery, Shenyang, China
1 shared publicationTianye Wang
Department of Medical Oncology, Nanjing Lishui People’s Hospital, Nanjing, China
1 shared publicationYunsa Huo
Department of Medical Oncology, Nanjing Lishui People’s Hospital, Nanjing, China
1 shared publication
Latest Publications
- Open Access
- 21 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 22779
Protein corona guided albumin-binding paclitaxel nanoparticles for treatment of intracranial tumors
- 21 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 22779
Open AccessProtein corona guided albumin-binding paclitaxel nanoparticles for treatment of intracranial tumors
- Open Access
- 9 September 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (9) , 1175
Integrating Microorganism-Based Therapy and Emerging Biotechnology in the Treatment of Intracranial Central Nervous System Diseases
The development of drug delivery systems for the treatment of intracranial central nervous system (CNS) diseases remains one of the most intractable medical problems in modern society, owing to the special physiological structure of the brain, including the existence of the blood-brain barrier (BBB), the CNS’s immune privilege, and its high complexity and vulnerability. Recently, a leading approach in the CNS drug delivery domain has been to employ or simulate the physiological behavior of microorganisms to overcome the BBB and remodel the pathological immune microenvironment in intracranial tissue. Considering the exceptional advancements in microorganism-based CNS drug delivery systems, it is imperative to review the latest breakthroughs. Herein, we summarize the emerging trends at the intersection of microorganism-based drug delivery systems and emerging biomedical technology for the treatment of CNS diseases, with a particular focus on preclinical research into microorganism-based drug delivery systems to combat CNS diseases, aiming to describe a credible landscape for further clinical trials.
- 9 September 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (9) , 1175
Open AccessIntegrating Microorganism-Based Therapy and Emerging Biotechnology in the Treatment of Intracranial Central Nervous System Diseases
The development of drug delivery systems for the treatment of intracranial central nervous system (CNS) diseases remains one of the most intractable medical problems in modern society, owing to the special physiological structure of the brain, including the existence of the blood-brain barrier (BBB), the CNS’s immune privilege, and its high complexity and vulnerability. Recently, a leading approach in the CNS drug delivery domain has been to employ or simulate the physiological behavior of microorganisms to overcome the BBB and remodel the pathological immune microenvironment in intracranial tissue. Considering the exceptional advancements in microorganism-based CNS drug delivery systems, it is imperative to review the latest breakthroughs. Herein, we summarize the emerging trends at the intersection of microorganism-based drug delivery systems and emerging biomedical technology for the treatment of CNS diseases, with a particular focus on preclinical research into microorganism-based drug delivery systems to combat CNS diseases, aiming to describe a credible landscape for further clinical trials.